Abstract:Iacopo Petrini, 1 Giuseppe Giaccone 2 1 Medical Oncology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy; 2 Weill-Cornell Medicine, Meyer Cancer Center, New York, NY, USA Correspondence: Giuseppe Giaccone, Weill-Cornell Medicine, Meyer Cancer Center, 1300 York Ave. 6th floor, Rm A603C, New York, NY, 10021, USA, Tel +1 646 962-4969, Email Amivantamab is a bispecific antibody that recognizes epidermal growth factor receptor (EGFR) and MET proto-oncogene (MET). In May 2021, the Food and Drug Administration gave an accelerated approval of amivantamab for the treatment of non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertions (Exon20ins) who progressed after platinum-based chemotherapy. Amivantamab prevents ligand binding to EGFR and MET and the dimerization of the receptors suppressing the downstream signal transduction. Moreover, amivantamab determines antibody dependent cellular cytotoxicity and down regulation of cell surface proteins through internalization of the receptor and trogocytosis. Preliminary results of the Phase I/IB CHRYSALIS trial demonstrated an objective response rate of 40% with a median duration of response of 11.1 months (95% CI 9.6-not reached) in 81 patients treated with amivantamab with pretreated NSCLC with Exon20ins EGFR mutations. In a different cohort of the CHRYSALIS trial, patients with Ex19del and L858R EGFR mutations were enrolled after progression on osimertinib. 121 and 45 patients received amivantamab or a combination with lazertinib, a third-generation tyrosine kinase inhibitor, respectively. The objective response rate was 19% and 36% in patients treated with amivantamab alone or in combination with lazertinib, with a median progression-free survival of 6.9 (95% CI: 3.2– 5.3) and 11.1 (95% CI: 3.7– 9.5) months, respectively. All 20 patients with Ex19del and L858R EGFR mutations who received amivantamab and lazertinib as their first line treatment achieved an objective response. Amivantamab is currently under evaluation in Phase III clinical trials for the first line treatment of NSCLCs with Exon20ins EGFR mutations in combination with chemotherapy (PAPILLON), for the first line therapy of Ex19del and L858R mutated NSCLCs in combination with lazertinib (MARIPOSA) and in combination with chemotherapy and lazertinib in NSCLCs who progressed on osimertinib (MARIPOSA-2). Keywords: amivantamab, exon 20 insertion of EGFR, NSCLC Amivantamab (JNJ-61186372) is a fully human monoclonal antibody with bispecific binding: one portion of its antigen-binding fragment (FAB) recognizes the epidermal growth factor receptor (EGFR), while the other one recognizes the MET proto-oncogene (MET) (Figure 1). Amivantamab has been generated using Genmab's DuoBody ® technology: a novel FAB-arm exchange platform. 1 JNJ-61186372 was selected through a screening of 40 possible bispecific molecules given by the combination of 8 different anti-EGFR and 5 anti-MET antibodies. Among them, amivantamab has been selected based on the binding affinity of the monovalent antibodies, capability to prevent MET and EGFR phosphorylation and ability to arrest proliferation in cell lines. 2 The binding of amivantamab to the extracellular portion of MET was demonstrated by crystal structure and the ability of the antibody to prevent HGF activation of the receptor was also confirmed. 2 Using insertional mutagenesis, the EGFR epitope recognized by amivantamab was found to be located in the third domain near the TGFα binding site in the proximity of the cetuximab epitope. 2 Figure 1 Bispecific structure of amivantamab with binding of EGFR and MET on the surface of the cells. Using surface plasmon resonance, the binding affinity of amivantamab to EGFR and MET were (KD) 1.43 and 0.04 nmol/L, respectively. 3 Amivantamab simultaneously binds the extracellular domains of EGFR and MET and blocks the ligand binding of each receptor in a dose-dependent manner. 3 Amivantamab blocks the binding of EGF to the extracellular domains of EGFR with an IC 50 of 10 nmol/L (measured by ruthenium-labeled EGF) and the binding of HGF to the extracellular domains of MET with an IC 50 of 30 nmol/L (measured by biotinylated-labeled HGF). The ability of amivantamab to block ligand-induced phosphorylation of EGFR and MET has been evaluated in a panel of cell lines with different levels of expression of the receptors. The degree of phosphorylation inhibition was proportional to the receptor density for both EGFR and MET. 3 Amivantamab blocks the ligand-induced phosphorylation of the receptors more potently than the corresponding monovalent antibodies. This effect is stronger against the less expressed rec -Abstract Truncated-

Subcutaneous Versus Intravenous Amivantamab, Both in Combination with Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results from the Phase III PALOMA-3 Study.

Subcutaneous versus Intravenous Amivantamab, both in Combination with Lazertinib, in Refractory EGFR-mutated NSCLC: Primary Results from the Phase 3 PALOMA-3 Study

Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.

Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study.

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial

Amivantamab compared with real-world therapies in patients with NSCLC with EGFR Exon 20 insertion mutations who have progressed after platinum doublet chemotherapy.

Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

Abstract CT054: Amivantamab in wild-type advanced non-small cell lung cancer after disease progression on checkpoint inhibition and chemotherapy: Results from the phase 1b CHRYSALIS study

A phase 2, open-label study of amivantamab in patients with previously treated advanced or metastatic gastric or esophageal cancer.

Nivolumab Versus Chemotherapy in Patients with Advanced Oesophageal Squamous Cell Carcinoma Refractory or Intolerant to Previous Chemotherapy (ATTRACTION-3): a Multicentre, Randomised, Open-Label, Phase 3 Trial

A Modified Phase 1 Clinical Trial of Abivertinib (ac0010), a Third-Generation EGFR Tyrosine Kinase Inhibitor, in Chinese Patients with EGFR-T790M-positive Non-Small Cell Lung Cancer

Amivantamab monotherapy in relapsed/refractory metastatic colorectal cancer: OrigAMI-1, an open-label, phase 1b/2 study.

Efficacy and Safety of Amivantamab in Advanced or Metastatic EGFR-Mutant Non-Small Cell Lung Cancer: A Systematic Review

Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma

A Multi-Center Phase II Study of Toripalimab with Chemotherapy in Patients with EGFR Mutant Advanced NSCLC Patients Resistant to EGFR TKIs: Efficacy and Biomarker Analysis.

An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations

Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy

Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer EGFR Exon 20 insertion mutations after platinum-based chemotherapy

Abstract CT249: Results from KEYMAKER-U01 substudy 3: a phase 2 umbrella study of pembrolizumab plus investigational agents in patients with non-small-cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy